Hjem › Kreft i gallesystemet › Tennessee
Kliniske studier for Kreft i gallesystemet i Tennessee
10 studier for Kreft i gallesystemet søker deltakere på steder i Tennessee.
Byer i Tennessee
Offisiell studietekst (engelsk)
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- SCRI Oncology Partners, Nashville
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06760819A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
- Research Site, Nashville
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07221253Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
- Vanderbilt Ingram Cancer Center, Nashville
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 24. sep. 2026 · NCT05523947Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Nashville
RekruttererFase 2
Alder 18 til 130 · Alle kjønn · Oppdatert 23. sep. 2026 · NCT05489211Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Sarah Cannon Research Institute, Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 10. sep. 2026 · NCT06293898A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 11. aug. 2026 · NCT05592626A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Erlanger Health, Inc, Chattanooga
- The West Clinic, Germantown
- SCRI Oncology Partners, Nashville
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 5. aug. 2026 · NCT06330064A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- SCRI - TriStar Medical Group Children's Specialists, Nashville
- SCRI Oncology Partners, Nashville
RekruttererFase 2
Alder 8 og eldre · Alle kjønn · Oppdatert 27. jul. 2026 · NCT05503797Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Sarah Cannon Research Institute, Nashville
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 6. mai 2026 · NCT06239194Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
- The West Clinic, Germantown
- University of Tennessee Medical Center, Knoxville
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. apr. 2026 · NCT05733598Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.